Literature DB >> 34407643

Are PROMs passing the message? A reflection with real-life migraine patients.

Raquel Gil-Gouveia1, António Gouveia Oliveira2.   

Abstract

BACKGROUND: Several patient-reported outcome measures are available to monitor headache impact, but are those reliable in real-life clinical practice?
METHODS: Two identical patient-reported outcome measures (HALT-90 and MIDAS) were applied simultaneously in each clinical visit to a series of patients treated with monoclonal antibodies for migraine and intra-individual agreement was evaluated using the intraclass correlation coefficients.
RESULTS: Our sample included 92 patients, 92.4% females, 45 years old on average. Moderate (0.50 to 0.75) and even poor (<0.50) ICC were observed in all but the first item of these patient-reported outcome measures in at least one evaluation. Over time, missing data were more frequent and no learning effect was detected. DISCUSSION: We observed intra-personal variation in reliability when answering patient-reported outcome measures, persisting in repeated applications, and a decrease in the motivation to respond, which should alert clinicians for these additional challenges in real-life clinical practice.

Entities:  

Keywords:  PROM; headache; migraine; outcomes evaluation; real-life clinical setting

Mesh:

Year:  2021        PMID: 34407643     DOI: 10.1177/03331024211034509

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  2 in total

1.  Galcanezumab effect on "whole pain burden" and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience.

Authors:  Marcello Silvestro; Alessandro Tessitore; Ilaria Orologio; Rosa De Micco; Lorenzo Tartaglione; Francesca Trojsi; Gioacchino Tedeschi; Antonio Russo
Journal:  J Headache Pain       Date:  2022-06-13       Impact factor: 8.588

2.  TIME, to move forward? comment on "a universal outcome measure for headache treatments, care-delivery systems and economic analysis".

Authors:  Raquel Gil-Gouveia
Journal:  J Headache Pain       Date:  2022-02-22       Impact factor: 7.277

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.